OS Therapies is a micro-cap oncology name whose entire public-company story now runs through a single question: whether regulators accept a small, single-arm survival signal in fully resected pulmonary metastatic osteosarcoma as enough for early market access. The company is not selling a product. It is trying to turn a Listeria-based HER2 immunotherapy, OST-HER2, into accelerated and conditional approvals across the United States, the United Kingdom, Europe, and Australia on the back of a Phase 2b dataset, while a Priority Review Voucher sits in the background as the cash prize that would dwarf the current equity value.
The September survival update is the medical event the equity has been waiting for. Treated patients showed a 71.2% three-year overall survival rate. A pooled historical control showed 45.8%. The company reports a p-value of 0.002. That comparison is also the entire regulatory argument, because the trial has no randomized control arm. Cash at mid-year sat at $0.2 million. Payables sat near $20 million. The June statements carry an explicit going-concern warning.
The next several months resolve whether Medicines and Healthcare products Regulatory Agency and European Medicines Agency alignment on historical controls travels to the Food and Drug Administration through Project Orbis. Management is targeting Biologics License Application and conditional marketing filings in the fourth quarter, and a confirmatory Phase 3 start in the United Kingdom as a precondition for those early-access paths. The market is already pricing a non-trivial chance of success. The question is whether an equity of this size can fund the filings, the trial, and the payables without giving the residual claim away.